Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23rd 13:30-16:15
International Advanced Drug Delivery Systems / Drug-Device Combinations Session
Stay tuned
Meeting Planning
Amy Zhang:Founder, ESC Medtech
Felix Huang:Director & CEO, ESC Medtech
13:30-13:35 Moderator
Joshua Liu (Moderator):VP . Marketing Operations Center
13:35-14:00 Frontiers of Drug-Device Combination Products
Senior Regulatory Expert
14:00-14:20 Frontiers of Drug-Device Combination Products
Zhen Gu:Assistant to the President of Zhejiang University, Director of the National Key Laboratory of Advanced Drug Delivery Systems; Fellow of the American Institute for Medical and Biological Engineering (AIMBE), the International Academy of Medical and Biological Engineering (IAMBE) and the Controlled Release Society (CRS)
14:20-14:40 Development of Drug-Device Combination Products Amid the Boom of Large-Volume Subcutaneous Formulations
Mico Chen:Co-founder&CTO, ESC Medtech
14:40-14:55 Regulatory Compliance for Pharmaceutical-Device Combination Products
John Lee:Chairman of Guangzhou Jiutai Pharmaceutical and Medical Equipment Technology Co., Ltd., and Chief Scientist of Boji Medical (in the field of medical devices).
14:55-15:35 Roundtable Discussion: International Development of Drug-Device Combination Products
Amy Zhang(Moderator):Founder, ESC Medtech
Zheng Wang:Co-founder & CEO, Baoji Pharmaceutical
Changqing Su:Chief Scientist, Pharmaceutical Research Institute, Fosun Wanbang Group
Quanmin Chen:Vice President, Formulation Product Development Department, WuXi Biologics
Mengjie Li:Quality/BD Head of 3SBio Inc.
15:35-16:15 Roundtable Discussion: Development Priorities for Enterprises and Service Providers in Drug-Device Collaboration
Felix Huang (Moderator):CEO, ESC Medtech
Yanhua Sun:Deputy Dean of Qilu Pharmaceutical Research Institute, Head of Peptide Drug Research Department
Xin Yao:China President & VP&GM of Pharma, NEA
Hongtao Wu:Vice President of CMC, Keymed Biosciences Inc. Keymed Biosciences Inc.
Linjie Kong:R&D Head of Biologics & Biomacromolecules, CHIA TAI Tianqing Pharmaceutical Group Co., Ltd.
July 23,09:00-12:00
Brain-Computer Interface Session
Stay tuned
Special Session Planning
Jinbiao Hou:Fund Partner, Triwise Capital
09:00-09:05 Opening Remarks
Dajie Tang:Chairman, Triwise Capital
09:05-09:25 Brain–Computer Interfaces for Chinese Language Processing
Jinsong Wu:Chief of Shanghai Key Laboratory of Clinical and Translational Brain-Computer Interface Research,Vice-chair (research), Neurosurgery,Huashan Hospital, Fudan University
09:25-09:45 Ultrasound Brain–Computer Interfaces: Opportunities and Challenges
Liang Guo:Distinguished Professor, Shanghai Jiao Tong University
09:45-10:05 Brain–Computer Interfaces: Connecting the Brain to the Future
Tiger H. Tao:Tiger H. Tao, Founder & Chief Scientist of NeuroXess
10:05-11:05 Panel Discussion I: Value Creation and Growth Opportunities in the Brain–Computer Interface Sector
Zhenhua Zheng Host:Managing Partner, Triwise Capital
Hui Huang:CEO, ConMind Medical
Quan Yuan:CFO, NuraNavX
Shujian Yu:MindBridge Technology, Chief Scientific Officer, Vrije Universiteit Amsterdam, Tenured Professor
Fangfang Fan:MindMatrixes, CEO
11:05-12:00 Panel Discussion II: The Brain–Computer Interface Sector: Investment Thesis and Strategic Opportunities
Jinbiao Hou (Host):Fund Partner, Triwise Capital
Xiaojuan He:General Manager, Huiying Private Equity Fund, Shanghai Huangpu Investment Holdings
Na Li:Managing Director, Hongyuan Huifu
Jiaojiao Lu:Partner, Step Holdings
Hao Guo:Deputy General Manager, Zheshang Securities Asset Management Co., Ltd.
Yuqin Zhang:Director, Proxima Capital
July 23,13:35–16:15
International Advanced Drug Delivery Systems & Combination Products
Stay tuned
Meeting Host
Liu Shuang: Vice President of Marketing Operations Center, Eansure Medical Technology
Meeting Planning
Amy Zhang:Founder, ESC Medtech
Felix Huang:Director & CEO, ESC Medtech
13:35-14:00 Registration Administration of Drug-Device Combination Products in China
Senior Regulatory Expert
14:00-14:20 Frontiers of Drug-Device Combination Products
Zhen Gu:Assistant to the President of Zhejiang University, Director of the National Key Laboratory of Advanced Drug Delivery Systems; Fellow of the American Institute for Medical and Biological Engineering (AIMBE), the International Academy of Medical and Biological Engineering (IAMBE) and the Controlled Release Society (CRS)
14:20-14:40 Development of Drug-Device Combination Products Amid the Boom of Large-Volume Subcutaneous Formulations
Liancheng Chen:CTO, ESC Medtech
14:40-14:55 Regulatory Compliance for Pharmaceutical-Device Combination Products
John Lee: Chairman of Guangzhou Jiutai Pharmaceutical and Medical Equipment Technology Co., Ltd., and Chief Scientist of Boji Medical (in the field of medical devices).
14:55-15:3 Roundtable Discussion: International Development of Drug-Device Combination Products
Amy Zhang (Moderator):Founder, ESC Medtech
Zheng Wang:Co-founder & CEO, Baoji Pharmaceutical
Changqing Su:Chief Scientist, Pharmaceutical Research Institute, Fosun Wanbang Group
Quanmin Chen:Vice President, Formulation Development & Clinical Manufacturing, WuXi Biologics
Mengjie Li:Head of Quality, 3SBio Inc.
Wenjie Xu:Senior Vice President & CBO, Yinno Pharmaceutical
15:35-16:15 Roundtable Discussion: Development Priorities for Enterprises and Service Providers in Drug-Device Collaboration
Felix Huang (Moderator):CEO, ESC Medtech
Yanhua Sun:Deputy Dean of Qilu Pharmaceutical Research Institute, Head of Peptide Drug Research Department
Hongtao Wu:Vice President of CMC, CanNova Biologics
Yingchun Li:Director, Biological Products Institute & Macromolecule CMC,R&D Institute, CHIA TAI Tianqing Pharmaceutical Group Co., Ltd.
Xin Yao:China President & VP&GM of Pharma, NEA